S

SanRo Clinical Research Group | Bryant, AR

Research site

(Unclaimed)

Location

3005 Corporate Center Drive, Bryant, Arkansas, United States of America

Site insights

Top conditions

Top treatments

Azetukalner

LY3502970

Oral

Orforglipron

SEP-4199

Metformin

SP-624

Icalcaprant

Centanafadine

JZP150

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 8 total trials

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling

Major Depressive Disorder

Drug: Azetukalner

Drug: Placebo

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Enrolling

Major Depressive Disorder

Drug: SP-624

Drug: Placebo

Locations recently updated

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling

Bipolar II Disorder

Bipolar I Disorder

Drug: Icalcaprant

Drug: Placebo for Icalcaprant

An Open-Label Study of Azetukalner in Major Depressive Disorder (X-NOVA-OLE)

X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult p...

Invitation-only

Major Depressive Disorder

Drug: Azetukalner